"Fondazione Monasterio"

During the past decade, Fondazione Toscana Gabriele Monasterio conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 3 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 3 clinical trials were completed. i.e. 30% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fondazione Toscana Gabriele Monasterio" #1 sponsor was "Boston Scientific Corporation" with 3 trials, followed by "Actelion" with 2 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored, "Eidos Therapeutics, a BridgeBio company" with 2 trials sponsored and "Abbott Medical Devices" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fondazione Toscana Gabriele Monasterio" #1 collaborator was "Chiltern International Inc." with 1 trials as a collaborator, "European Association of Cardiovascular Imaging" with 1 trials as a collaborator, "Istituto Di Ricerche Farmacologiche Mario Negri" with 1 trials as a collaborator, "Ministry of Health, Italy" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Fondazione Toscana Gabriele Monasterio" are "Heart Failure" (4 trials), "Atrial Fibrillation" (3 trials), "Pulmonary Arterial Hypertension" (2 trials), "Stroke" (2 trials) and "Amyloid Cardiomyopathy" (1 trials). Many other conditions were trialed in "Fondazione Toscana Gabriele Monasterio" in a lesser frequency.

Most popular intervention types in "Fondazione Toscana Gabriele Monasterio" are "Drug" (13 trials), "Device" (7 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "2-lead CRT defibrillator system implantation" (1 trials), "4 mg elamipretide" (1 trials), "40 mg elamipretide" (1 trials) and "Acoramidis (AG10)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fondazione Toscana Gabriele Monasterio" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Fondazione Toscana Gabriele Monasterio". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in Fondazione Toscana Gabriele Monasterio, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Fondazione Toscana Gabriele Monasterio, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".

Fondazione Toscana Gabriele Monasterio has several departments that took part in Clinical trials: "Ftgm - Stabilimento Di Massa - Uoc Cardiologia Diagn. E Interventistica" - 2 trials